---
title: "Leap Therapeutics Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch Digital Asset Treasury Strategy"
description: "Leap Therapeutics Inc. has announced a $58.88 million private placement led by Winklevoss Capital to support its new digital asset treasury strategy. The financing includes the sale of approximately 9"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260056300.md"
published_at: "2025-10-06T13:02:18.000Z"
---

# Leap Therapeutics Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch Digital Asset Treasury Strategy

> Leap Therapeutics Inc. has announced a $58.88 million private placement led by Winklevoss Capital to support its new digital asset treasury strategy. The financing includes the sale of approximately 95.8 million shares of common stock and additional warrants for about 71.9 million shares at an exercise price of $0.5335 per share. The closing of the private placement is expected soon, pending customary conditions. Parcrest is the placement agent, with legal advice from Morgan, Lewis & Bockius LLP and Cooley LLP.

Leap Therapeutics Inc. (Nasdaq: LPTX), a biotechnology company specializing in targeted and immuno-oncology therapies, has announced a $58.88 million private placement led by Winklevoss Capital. The financing involves the sale of approximately 95.8 million shares of common stock or pre-funded warrants, along with additional warrants to purchase about 71.9 million shares at an exercise price of $0.5335 per share. The aggregate exercise price per unit is set at $0.61439. The funds raised will support Leap’s newly initiated digital asset treasury strategy. Parcrest is serving as the placement agent, with Morgan, Lewis & Bockius LLP advising Leap and Cooley LLP advising Winklevoss Capital. The closing of the private placement is expected soon, pending customary closing conditions. Leap plans to provide further updates on its treasury activities in the near term. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE90771) on October 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [LPTX.US - Leap Therap](https://longbridge.com/en/quote/LPTX.US.md)
- [CYPH.US - Cypherpunk Tech](https://longbridge.com/en/quote/CYPH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SGT Capital 關閉人工智能共同投資基金 | SGT Capital 成功關閉了其人工智能（AI）共同投資基金，該基金超額認購 25%。該基金旨在增強 SGT Capital 在數據分析、網絡安全和醫療科技領域的投資策略。該公司強調了對 AI 驅動商業模式日益增長的需求，並計劃在北美、 | [Link](https://longbridge.com/en/news/276220446.md) |
| ZAWYA-PRESSR: Arboris Capital Limited 推出其 CapGain 平台 | Arboris Capital Limited 推出了 CapGain®，這是一個以技術驅動的平台，旨在為專業客户和市場對手提供私募市場機會的訪問。該平台通過將機會審查和盡職調查等關鍵流程整合到一個數字環境中，解決了價值 22 萬億美元的私 | [Link](https://longbridge.com/en/news/276051332.md) |
| Advik Capital 稱德里高等法院授予了臨時資產保護 | Advik Capital Ltd：ADVIK CAPITAL LTD - 德里高等法院授予 ADVIK CAPITAL 臨時資產保護 | [Link](https://longbridge.com/en/news/276062688.md) |
| Palvella Therapeutics (PVLA) 獲得了 Craig-Hallum 的買入評級 | 在最近的一份報告中，Craig-Hallum 分析師 Albert Lowe 對 Palvella Therapeutics (PVLA) 維持了買入評級，目標價為 205.00 美元。Lowe 是一位四星級分析師，平均回報率為 8.4%， | [Link](https://longbridge.com/en/news/276240277.md) |
| GSA Capital Partners LLP 增加了對 Edgewise Therapeutics, Inc. $EWTX 的持股 | GSA Capital Partners LLP 在第三季度將其在 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) 的持股增加了 315.2%，目前持有 113,243 股，價值 184 萬美元。其他對沖 | [Link](https://longbridge.com/en/news/276119404.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.